Promoting Your 510(k)-Pending Device: 5 Questions About FDA's Policy
A 510(k) submission rather than a 510(k) clearance is the threshold that a device firm needs to meet to begin advertising or displaying a product under a long-established, one-sentence agency policy. But important questions remain about proper application of this policy by industry, Hyman, Phelps & McNamara attorney Jeffrey Shapiro writes in this guest column.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.